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Abstract
Recent studies in the SIV-macaque model of HIV infection suggest that Nef-specific CD8+ T-cell responses may
mediate highly effective immune control of viraemia. In HIV infection Nef recognition dominates in acute infection, but
in large cohort studies of chronically infected subjects, breadth of T cell responses to Nef has not been correlated
with significant viraemic control. Improved disease outcomes have instead been associated with targeting Gag and,
in some cases, Pol. However analyses of the breadth of Nef-specific T cell responses have been confounded by the
extreme immunogenicity and multiple epitope overlap within the central regions of Nef, making discrimination of
distinct responses impossible via IFN-gamma ELISPOT assays. Thus an alternative approach to assess Nef as an
immune target is needed. Here, we show in a cohort of >700 individuals with chronic C-clade infection that >50% of
HLA-B-selected polymorphisms within Nef are associated with a predicted fitness cost to the virus, and that HLA-B
alleles that successfully drive selection within Nef are those linked with lower viral loads. Furthermore, the specific
CD8+ T cell epitopes that are restricted by protective HLA Class I alleles correspond substantially to effective SIV-
specific epitopes in Nef. Distinguishing such individual HIV-specific responses within Nef requires specific peptide-
MHC I tetramers. Overall, these data suggest that CD8+ T cell targeting of certain specific Nef epitopes contributes
to  HIV  suppression.  These  data  suggest  that  a  re-evaluation  of  the  potential  use  of  Nef  in  HIV  T-cell  vaccine
candidates would be justified.
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Introduction
The HIV-1 nef gene encodes a polymorphic 27kda protein,
200-215 amino acids in length [1,2]. Nef has a complex role in
HIV  pathogenicity  via  a  number  of  mechanisms,  including
down-regulation of host CD4 and MHC cell surface expression,
modulation  of  T  cell  function,  and  altering  of  macrophage
signaling [2–4]. Nef is among the most diverse HIV proteins [5].
The greatest sequence variability is focused in the amino- (N-)
and carboxy- (C-) terminal regions, while the central portion of
the protein is substantially more conserved [6–8]. At least some
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73117of  this  sequence  variability  may  be  driven  by  Class  I  HLA
selection pressure [9,10].
Nef has a high density of overlapping CD8+ T cell epitopes
(see Nef epitope map at www.hiv.lanl.gov), and multiple copies
of Nef are produced early in the HIV life cycle [11,12]. Nef is
the most targeted protein in acute infection [13–15], accounting
for 50% to 90% of CD8+ T cell responses in acutely infected
subjects  [16,17],  as  well  as  having  the  most  CD8+  T  cell
responses and the highest magnitude IFN-gamma responses
in chronic infection [7].
Large  cross-sectional  studies  have  shown  no  correlation
between viraemic suppression and either the breadth of CD8+
T  cell  IFN-gamma  responses  to  Nef  [18],  or  the  number  of
HLA-selected  mutations  in  Nef  [19].  However  the
immunogenicity of Nef and consequent density of overlapping
epitopes  confounds  analyses  of  the  distinct  CTL  responses
targeting this protein that have typically depended on ELISpot
assays using panels of overlapping peptides 15-18 amino acids
in length. Other studies have attempted to address the issue of
Nef diversity by using extended panels of overlapping peptides
(e.g. 10-mers overlapping by 9 amino acids, with all common
variants represented [20]) but this approach is costly and time-
consuming.
The HLA Class I alleles that are most strongly associated
with  long-term  suppression  of  viraemia  (e.g.  HLA-B*57,  -
B*58:01 and -B*27 [21–23]) present CD8+ T cell epitopes in
Gag and Pol that have been especially well-studied [19,24,25].
The targeting of these highly conserved proteins is thought to
underpin  successful  immunological  control  [26,27].  However
these HLA class I molecules also present epitopes within Nef
that may be important in mediating disease control. In a host
expressing  these  protective  HLA  alleles,  the  virus  adapts  by
selecting escape mutations in all Gag, Pol and Nef epitopes
[28,29],  underlining  a  survival  benefit  to  the  virus  incurred
through  evasion  of  these  responses.  Indeed,  some  studies
have  suggested  that  viraemic  suppression  may  be  linked  to
specific Nef epitopes, including HLA-B*57/58:01-HW9 [30] and
HLA-B*35: 01-VY8 [31].
Several  further  lines  of  evidence  pointing  towards  the
potential immunological benefit of targeting HIV-Nef have been
reported. Many HLA-selected escape mutations in Nef revert to
wild-type  following  transmission  to  an  HLA-mismatched  host,
suggesting  a  fitness  cost  in  association  with  the  mutation
[9,19].  This  hypothesis  is  supported  first  by  studies  showing
that  Nef  polymorphisms  are  more  common  among  slow
progressors  than  rapid  progressors  [6],  and  second  by  the
finding  that  such  sequence  changes  in  elite  controllers  are
associated with a detriment to Nef function [32].
Studies in the SIV model add further weight to the hypothesis
that  Nef  responses  can  contribute  to  disease  control.  In  the
rhesus  macaque,  Mamu-B*08,  which  has  a  peptide-binding
motif so similar to HLA-B*27 that it can bind the same peptides
[33],  is  also  associated  with  elite  viraemic  control  [34–36].
However,  unlike  HLA-B*27  [25],  the  immunodominant
responses  are  within  accessory/regulatory  proteins,  and  a
vaccine  induced  Mamu-B*08-restricted  response  to  the  Nef
RL10 epitope (SIV Nef 137–146, RRHRILDIYL) is correlated
with viraemic control [34]. This epitope is homologous to the
HIV-specific  HLA-B*27:  05  RI10  epitope,  (HIV  Nef  105-114,
RRQDILDLWI  [37]).  Likewise,  macaques  expressing  another
favourable  allele,  Mamu-B*17,  also  target  Nef  via  two
immunodominant  epitopes,  IW9  (SIV  Nef  165-173,
IRYPKTFGW)  and  MW9  (SIV  Nef  195-203,  MHPAQTSQW)
[38,39]. In Mauritian Cynomolgus Macaques, controllers of SIV
replication  have  been  shown  to  target  epitopes  located  near
the carboxy terminus of the SIV Nef protein [40]. Recently, a
novel protective MHC-I haplotype was described in Burmese
macaques, 90-010-Id (D), which also mediates immune control
against SIV through Nef responses [41].
The starting point for these current studies, therefore, was
the conflict in evidence regarding the extent to which CD8+ T
cell responses to Nef might impact upon HIV-1 disease control.
On the one hand, large cross-sectional studies have suggested
no benefit in extended breadth of Nef targeting [18,19], whilst
on  the  other,  recent  data  suggest  that  targeting  particular
regions  of  Nef  might  contribute  fundamentally  to  viraemic
control [29–32,34,38,39].
Most previous analyses of Nef diversity and HLA-selection
have focused on B-clade infections [12,29,42,43], while studies
of C-clade have often been limited by small sample numbers
[44,45]. We focused here on an extended cohort of >700 C-
clade infected adults to identify relationships between CD8+ T
cell  responses  to  Nef  and  HIV  disease  control.  We
hypothesized that certain specific Nef responses may help to
underpin viraemic control, strengthening the argument for the
inclusion of Nef as an immunogen in CD8+ T cell vaccines.
Materials and Methods
Recruitment and characterization of HIV-infected
individuals
We studied 739 adults with chronic HIV-1 C-clade infection
recruited  from  three  cohorts:  Durban,  South  Africa  (n=436),
Gaborone,  Botswana  (n=275),  and  Zimbabwean  subjects
recruited via the Thames Valley Cohort in the UK (n=28), as
previously  described  [46,47].  Ethics  approval  was  given  by
KwaZulu-Natal Review Board and the Massachusetts General
Hospital Review Board (Durban cohort); the Office of Human
Research Administration, Harvard School of Public Health and
the  Health  Research  Development  Committee,  Botswana
Ministry of Health (Gaborone cohort); and the Oxford Research
Ethics  Committee  (Durban,  Gaborone  and  Thames  Valley
cohorts). All subjects provided written informed consent.
Nef sequences and HLA-types were generated as previously
described [19,48]. Viral loads were performed using the Roche
Amplicor v.1.5 assay. Viral load measurements were made in
chronic disease (therefore reflecting set-point viraemia).
Identification of Nef sequence polymorphisms
associated with Class I HLA genotype
We  used  computational  methods,  as  previously  described
[19,49], to identify sites of HLA-selected polymorphism in Nef
sequences,  correcting  for  viral  lineage  and  for  linkage
disequilibrium between HLA Class I alleles. We corrected for
multiple  comparisons  using  a  q-value  (false  discovery  rate,
FDR [50]), and a cut-off value of q<0.05(5% FDR). Reversion
CD8+ T Cell Responses to HIV Nef
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between the absence of a particular HLA allele with either (i) an
increase in expression of the consensus amino acid, or (ii) a
decrease  in  expression  of  a  variant  amino  acid  [19].  These
associations  demonstrate  that  a  mutation  selected  by  a
particular  HLA  allele  returns  to  consensus  following
transmission to an HLA-mismatched host, from which a fitness
cost is inferred.
Data analysis
We computed amino acid variability using Shannon entropy
with  the  on-line  tool  at  Los  Álamos  HIV  sequence  database
(http://www.hiv.lanl.gov/content/sequence/ENTROPY/
entropy_one.html).  Mean  entropy  scores  were  calculated  for
each  overlapping  peptide  (OLP)  spanning  the  Nef  protein
(OLPs  67-93)  and  ranged  from  0.15  in  a  ‘conserved’  region
(OLP-82) to 0.78 in a ‘non-conserved’ region (OLP-68).
Statistical analysis was performed using GraphPad Prism v.
5.0a. We focused our attention particularly on the central, most
conserved region of Nef (previously defined as residues 81-160
[8]),  extended  here  to  correspond  to  the  most  conserved
overlapping  peptides  (OLPs)  adopted  in  these  and  in
previously published studies [51], namely OLPs 76-85.
IFN-gamma ELISpot studies to identify regions of the
Nef protein associated with beneficial immune
responses
In vitro HIV-specific CD8+ T-cell responses were determined
in a cohort of 1010 subtype-C infected individuals using IFN-
gamma ELISpot assays using a set of 410 overlapping 18-mer
OLPs  spanning  the  whole  HIV-1  subtype  C  proteome  (2001
consensus sequence). Overlapping peptides were arranged in
a matrix system with 11-12 peptides in each pool. Responses
to matrix pools were confirmed by subsequent testing with the
individual 18-mer peptides within each pool, and the identity of
the  individual  18-mers  recognized  were  thus  confirmed,  as
previously described [46].
OLP  responses  that  independently  correlate  with  log10  VL
were  identified  using  stepwise  linear  regression  (inclusion
criterion: p<0.05; exclusion criterion: p>0.05). We included in
analysis  all  OLPs  for  which  responses  were  observed  in  ≥3
individuals, and HLA class I alleles expressed in ≥3 individuals.
P-values  were  computed  using  likelihood  ratio  tests,  and  q-
values  were  computed  over  all  features,  conditioned  on  the
final  model.  For  these  studies,  the  analyses  resulting  in  q
values <0.2 (p<0.024) were defined as significant.
HLA Class I tetramer staining
Tetramers were generated as previously described [52]. We
stained  antigen-specific  cells  using  peptide-MHC-I  tetramer
conjugated  to  phycoerythrin  (PE)  or  allophycocyanin  (APC).
Peripheral blood mononuclear cells (PBMCs) were thawed in
R10 medium (RPMI medium, 10% fetal calf serum [FCS], 1%
penicillin/streptomycin, 1% glutamine); rested for 1 h at 37°C in
5% CO2; stained with HLA class I tetramer for 30 min at room
temperature;  washed;  surface  stained  with  CD8  Pacific  Blue
(BD Pharmingen), CD3 Pacific Orange (Invitrogen), and a live/
dead  violet  cell  stain  kit  (Invitrogen)  for  30  min;  washed  in
phosphate-buffered  saline  (PBS)  and  fixed  in  2%
paraformaldehyde. Data were acquired on an LSR II (BD) flow
cytometer within 12 h of staining and analyzed using FlowJo
version 8.8.6. The cells were hierarchically gated on singlets,
lymphocytes,  live  cells,  and  distinct  tetramer-specific  CD8-
positive cells.
Results
Over 50% of HLA-selected polymorphisms in Nef are
predicted to reduce viral fitness
Sequence  analysis  identified  44  Nef  sequence
polymorphisms  associated  with  Class  I  HLA  expression,
operating at 34 different amino acid residues (all associations
corrected  for  multiple  comparisons,  q<0.05  [49];  Table  1).
Reversion  was  predicted  following  transmission  to  an  HLA-
mismatched  recipient  in  24  of  the  44  HLA-associated
polymorphisms  (54.5%)  (Table  1),  implying  that  these
polymorphisms  would  occur  at  a  cost  to  viral  replicative  or
infective capacity [19,49].
Of  the  44  HLA-associated  polymorphisms  identified,  25
(57%) were within or in the flanking regions (within 5 amino
acids up- or down-stream) of known epitopes restricted by the
HLA  allele  in  question  (Table  1).  The  majority  of
polymorphisms  (n=31,  70%)  were  associated  with  HLA-B
alleles, while 7 (16%) were associated with HLA-A and 6 (14%)
with HLA-C (Table 1).
HLA-mediated selection pressure contributes to
sequence diversity in conserved central Nef
Nef can be divided into three regions of differing sequence
variability  (Figure  1).  The  central  region  (residues  66-148,
median  residue  entropy  0.135)  is  the  most  conserved,
significantly more so than both the C-terminal region (residues
149-206,  median  residue  entropy  0.491,  p  <  0.0001,  Mann–
Whitney  U  test),  and  the  N-terminal  region  (residues  1-65,
median residue entropy 0.829, p < 0.0001, Mann–Whitney U
test).  The  C-terminal  region  is  significantly  more  conserved
than the N-terminal region (p=0.0056, Mann–Whitney U test).
There is a strong relationship between the presence of an
HLA-selected  polymorphism  and  amino  acid  variability,
particularly in the central conserved region of Nef (p=0.0001,
Mann–Whitney  U  test;  Figure  1B).  Although  this  type  of
analysis  cannot  determine  the  causation  of  amino  acid
diversity, this association may indicate that HLA is a significant
factor in driving polymorphisms, as previously suggested with
Gag sequences [10] and supported in studies of longitudinally
sampled  Nef  sequences  [53].  This  illustrates  the  potential
evolutionary influence of HLA-selection in Nef [29,54], 47], as a
factor  contributing  to  sequence  diversity,  together  with  other
factors such as neutral ‘toggling’ between amino acids, founder
effect and genetic drift [55].
HLA-B selected mutations in Nef are associated with
reduction in viral set-point
We next investigated the relationship between the presence
of  polymorphisms  selected  by  HLA-A,  HLA-B  and  HLA-C
CD8+ T Cell Responses to HIV Nef
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driving the selection of Nef mutants are linked with lower VL
than those that do not select Nef polymorphisms (median VL
21,175  RNA  copies/ml  versus  49,350  for  HLA-B  alleles  not
associated with any Nef selection; p=0.003, Mann Whitney U
test;  Figure  2).  However,  increasing  the  number  of  Nef
mutations beyond 1 was not statistically associated with HLA-B
alleles  predictive  of  lower  VL.  There  was  no  significant
Table 1. Amino acid residues in Nef at which amino acid polymorphism is associated with HLA Class I expression.
HLA HXB2 position                                           P value q value Reversion
A*68:01 15 W S K S S I V G W P A V R E R I R R T E P 5.00E-07 0.00  
A*24:02 135 Q N Y T P G P G V R Y P L T F G W C F K L 4.40E-05 0.02 R
A*23 143 V R Y P L T F G W C F K L V P V D P R E V 8.52E-17 0.00 R
A*66:01 156 V P V D P R E V E E A N K G E N N C L L H 2.87E-05 0.01 R
A*02 176 H P M S Q H G M E D E D R E V L K W K F D 1.07E-05 0.01  
A*66 184 E D E D R E V L K W K F D S S L A R R H L 6.70E-05 0.02 R
A*74:01 192 K W K F D S S L A R R H L A R E L H P E Y 2.89E-06 0.00 R
B*73:01 19 S I V G W P A V R E R I R R T E P A A E G 1.53E-04 0.05  
B*42 20 I V G W P A V R E R I R R T E P A A E G V 7.22E-05 0.03  
B*44(03) 64 C A W L E A Q E E E E V G F P V R P Q V P 2.52E-08 0.00 R
B*4501 64 C A W L E A Q E E E E V G F P V R P Q V P 3.90E-08 0.00  
B*4501 66 A W L E A Q E E E E V G f P V R P Q V P L 1.50E-26 0.00 R
B*44(03) 71 E E E E E V G F P V R P Q V P L R P M T Y 5.23E-06 0.00 R
B*07 [Cw*07:02] 71 E E E E E V G F P V R P Q V P L R P M T Y 2.16E-13 0.00 R
B*57 76 V G F P V R P Q V P L R P M T Y K A A F D 5.55E-05 0.02 R
B*81(01) 76 V G F P V R P Q V P L R P M T Y K A A F D 2.71E-23 0.00  
B*35(01) 81 R P Q V P L R P M T Y K A A F D L S F F L 8.22E-11 0.00  
B*57 83 Q V P L R P M T Y K A A F D L S F F L K E 2.41E-07 0.00  
B*5801 [A*03] 83 Q V P L R P M T Y K A A F D L S F F L K E 1.16E-12 0.00 R
B*44(03) 93 A A F D L S F F L K E K G G L E G L I Y S 2.48E-15 0.00 R
B*44:03 102 K E K G G L E G L I Y S K K R Q E I L D L 1.57E-18 0.00 R
B*18(01) 108 E G L I Y S K K R Q E I L D L W V Y H T Q 1.36E-11 0.00  
B*44:03 108 E G L I Y S K K R Q E I L D L W V Y H T Q 1.08E-09 0.00  
B*44:03 115 K R Q E I L D L W V Y H T Q G F F P D W Q 1.25E-04 0.04 R
B*57:03 116 R Q E I L D L W V Y H T Q G F F P D W Q N 8.93E-06 0.01  
B*35(01) 133 D W Q N Y T P G P G V R Y P L T F G W C F 3.32E-08 0.00  
B*53(01) 133 D W Q N Y T P G P G V R Y P L T F G W C F 3.12E-05 0.01  
B*42 133 D W Q N Y T P G P G V R Y P L T F G W C F 4.75E-05 0.02 R
B*14:01 156 V P V D P R E V E E A N K G E N N C L L H 5.46E-05 0.02  
B*13 158 V D P R E V E E A N K G E N N C L L H P M 1.89E-05 0.01 R
B*42 168 K G E N N C L L H P M S Q H G M E D E D R 1.75E-05 0.01  
B*42 173 C L L H P M S Q H G M E D E D R E V L K W 4.11E-05 0.02 R
B*15:01 176 H P M S Q H G M E D E D R E V L K W K F D 1.18E-05 0.01  
B*53(01) 176 H P M S Q H G M E D E D R E V L K W K F D 2.14E-05 0.01 R
B*08:01 179 S Q H G M E D E D R E V L K W K F D S S L 1.24E-04 0.04  
B*15:10 191 L K W K F D S S L A R R H L A R E L H P E 5.99E-06 0.00 R
B*35(01) 194 K F D S S L A R R H L A R E L H P E Y Y K 1.02E-05 0.01 R
B*42:01 202 R H L A R E L H P E Y Y K D C             4.76E-05 0.02  
Cw*02:10 48 K H G A L T S S N T A H N N A D C A W L E 1.51E-04 0.05  
Cw*08 85 P L R P M T Y K A A F D L S F F L K E K G 3.19E-05 0.01 R
Cw*07:01 [B*080 105 G G L E G L I Y S K K R Q E I L D L W V Y 2.93E-14 0.00 R
Cw*16:01 174 L L H P M S Q H G M E D E D R E V L K W K 1.13E-04 0.04  
Cw*16 198 S L A R R H L A R E L H P E Y Y K D C     1.26E-05 0.01 R
Cw*16 199 L A R R H L A R E L H P E Y Y K D C       1.44E-05 0.01 R
Bold interface indicates site of polymorphism
Lineage-corrected analysis of sequences from 739 C-clade infected Southern African subjects. Amino acid residue at which polymorphism is identified is shown in bold, with
ten amino acids flanking on either side (consensus sequence for this cohort). Known HLA-class I epitopes corresponding to the allele in question are underlined. Sites at
which reversion is predicted are marked ‘R’ [19]. Round brackets indicate likely high resolution HLA type based on high population prevalence of this allele. Square brackets
indicate alleles in linkage disequilibrium with selecting allele, with association also detected at this site.
CD8+ T Cell Responses to HIV Nef
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for HLA-A and HLA-C alleles (p=0.2 and p=0.5, respectively,
Figure 2).
Given the relationship between HLA-B selection in Nef and
reduced  VL,  we  further  scrutinized  the  pattern  of  HLA-B-
associated  polymorphisms.  The  commonest  HLA-B  alleles
driving selection were HLA-B*44 (n=6; 14% of all associations),
HLA-B*42  (n=5;  11%),  HLA-B*57  (n=3;  7%)  and  HLA-B*35
(n=3; 7%) (Table 1). All of these alleles have been associated
with  favourable  control  of  viraemia  in  previous  studies  of  C-
clade infected cohorts [31,56–58]. This includes HLA-B*35: 01,
which is associated with rapid progression in B-clade infection
but  not  in  C-clade  infection  [31].  The  presence  of  a  strong
CD8+ T cell response directed at Nef by all of these alleles is
again  consistent  with  the  hypothesis  that  specific  Nef
responses may be a component of successful disease control.
Definition of novel HLA-B*44:03 restricted Nef epitopes
HLA-B*44  is  responsible  for  the  greatest  number  of  HLA-
selected  polymorphisms  in  Nef  (Table  1),  but  there  are  no
epitopes restricted by HLA-B*44 that have been sufficiently well
defined  to  appear  in  the  Los  Álamos  epitope  ‘A-list’  (http://
www.hiv.lanl.gov/content/immunology/tables/
optimal_ctl_summary.html).  In  Southern  Africa,  the
predominant  HLA-B*44  subtype  is  HLA-B*44:  03.  For  these
reasons, we focused on further identification of HLA-B*44: 03
epitopes.  The  approach  we  used  for  guidance  was,  first,  to
identify the Nef residues at which HLA-B*44: 03 drives escape,
then  to  predict  the  optimal  epitope  based  on  the  peptide-
binding motif for HLA-B*44: 03, which features glutamate (E) at
position  2,  and  phenylalanine  (F)  or  tyrosine  (Y)  at  the  C-
terminus  [59,60].  We  thus  identified  Nef  93-102
(KEKGGLEGLIY;  locations  of  HLA-escape  associations
Figure 1.  Variation in C-clade Nef sequences, and relationship between amino acid variability and presence of HLA-class I
selection pressure.  [A] Nef consensus sequence (derived from 739 C-clade sequences from Southern African patients) plotted
against Shannon entropy score. Residues at which there is an association with HLA-Class I expression are shown in grey. As
previously observed, the sequence is most highly conserved in the central portion of the protein (residues 66-148) [8]..
[B] Entropy scores of residues associated with HLA-class I expression vs. those with no HLA association, showing significantly
higher variability at sites at which HLA selection operates, particularly in the central conserved region. P-value by Mann Whitney U
test.
doi: 10.1371/journal.pone.0073117.g001
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B*44: 03-restricted epitopes. We subsequently confirmed these
epitopes using HLA-B*44: 03 tetramers bound to KY11 or QY9
(Figure 3). In both epitopes, the putative escape mutations are
located  exclusively  at  the  anchor  residues,  consistent  with
recent studies indicating a tendency for selection of escape at
anchor residues [61], especially among protective alleles. The
location of these epitopes, which overlap with others presented
by highly protected MHC-I alleles (Figure 4), as well as with
many others within the central highly immunogenic region of
Nef  (see  epitope  map  at  http://www.hiv.lanl.gov/content/
immunology/maps/ctl/Nef.html)  would  make  precise
identification,  quantification  and  analysis  of  such  responses
highly problematic without access to such tetrameric reagents.
Figure 2.  Relationship between number of HLA associations with Nef sequence polymorphisms and median viral load for
subjects  expressing  that  allele,  for  HLA-A,  -B  and  -C  alleles.    Data  from  lineage-corrected  analysis  of  739  C-clade  Nef
sequences. P-values by Mann–Whitney U test.
doi: 10.1371/journal.pone.0073117.g002
Figure 3.  Confirmation of Nef-KY11 (KEKGGLEGLIY) and Nef-QY9 (QEILDLWVY) as novel HLA-B*44: 03 restricted.  CD8 T
cell epitopes using HLA-Class I tetramers. HLA-B*44: 03 tetramers were loaded with [A] Nef-KY11 and [B] Nef-QY9 optimal
peptide and stained against donor PBMC’s from a C-clade infected B*44: 03 positive individual, subject R129 HLA-A*23: 01/30:04,
B*08: 01/44:03, C*03:04/04:01. The number shown above each gate is the percentage of total lymphocytes that are tetramer-
specific (tetramer positive cells expressed as a percentage of CD8+ cells were 1.48% for KY11 and 0.65% for QY9).
doi: 10.1371/journal.pone.0073117.g003
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associated with lower viral load set-point
Our  analyses  of  this  extended  dataset  confirmed  previous
findings  [51]  of  a  statistically  significant  relationship  between
reduced VL and IFN-gamma ELISpot T cell responses to two
OLPs  in  Nef,  with  q<0.2:  OLP-79  SFFLKEKGGLEGLIYSKK
(p=0.01,  q=0.13),  and  OLP-85,  RYPLTFGWCFKLVPV
(p=0.002, q=0.04).
Examining  these  regions  in  more  detail,  the  Nef  regions
spanned by OLP-79 and OLP-85 contain epitopes restricted by
HLA-B*27,  HLA-B*44  and  HLA-B*57  [28]  (http://
www.hiv.lanl.gov/content/immunology/ctl_search  and  [14])  as
well as by the protective macaque MHC-I alleles Mamu-B*08
and Mamu-B*17 and the protective Burmese rhesus monkey
haplotype  90-010-Id  (D)  (Figure  4).  Together,  these  data
suggest  that  responses  to  these  regions  of  Nef  may  be
especially  beneficial  and  contribute  to  MHC-I-associated
protection against HIV/SIV disease.
Discussion
We have here shown, using several approaches, that CD8+
T  cell  responses  to  HIV  Nef  can  be  linked  with  improved
viraemic suppression. First, HLA-selected escape mutations in
Nef  have  a  high  rate  of  reversion  to  wild-type  following
transmission,  suggesting  a  fitness  cost  imposed  by  the
mutation  in  the  presence  of  the  selecting  allele.  Second,
targeting  of  two  specific  OLPs  in  Nef  is  associated  with
reduction in viraemia in chronic infection, pointing to successful
T cell responses in these regions. Third, there is substantial
overlap between Nef regions targeted by beneficial HLA Class I
epitopes  and  by  simian  Mamu-restricted  responses  that  are
associated with disease control.
The finding that HLA alleles predictive of lower viraemia are
statistically  associated  with  selection  of  one  or  more  HLA-
selected polymorphisms in Nef points to a contribution of CD8+
T  cell  responses  to  Nef  in  mediating  disease  control.  It  is
Figure 4.  Map of central region of Nef showing sites of key epitopes and residues at which CD8+ selection pressure
operates.  Central conserved region of HIV-1 Nef is shown previously defined as HXB2 residues 81-160 [8]. Corresponding B-clade
and C-clade consensus sequences are shown along with SIVmac239 consensus. Positions of epitopes restricted by alleles HLA-
B*27 [37], HLA-B*57 [28,64,65] and HLA-B*44 are highlighted in green, orange and blue respectively. Regions homologous to
Mamu-B*08 [36] and Mamu-B*17 epitopes [66] are also marked (yellow and purple respectively). SIV 115-129 also highlighted as a
region recently associated with SIV control in macaques [41]. Responses to overlapping peptides 79 and 85 are associated with
viraemic control, q<0.2 (black boxes). Sites of mutations selected by HLA-B*57, HLA-B*27, HLA-B*44, Mamu-B*08 and Mamu-B*17
are marked with arrows [29,36,67]. This highlights the substantial overlap between HIV and SIV epitopes restricted by alleles that
are associated with favourable immune control.
doi: 10.1371/journal.pone.0073117.g004
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by comparison of viral loads in subjects with and without those
mutants.  If  the  mutation  is  associated  with  a  significantly
increased viral load this may suggest that the CTL response
contributes  to  immune  control  and  if  there  is  no  significant
increase  that  it  does  not.  However,  a  lack  of  significant
increase in viral load associated with selection of the escape
mutant may reflect reduced replicative capacity resulting from
that mutation and a fine balance between selection pressure
driven by the CTL response and opposing purifying selection
pressure exerted by the virus. The fact that 5 out of the 6 B*44:
03-associated Nef mutations were predicted to be revertants,
that is, induced a cost to viral replicative capacity, underlines
the  intractability  of  such  analyses.  For  these  reasons,  we
cannot draw specific conclusions about the effects of selection
of one or more Nef polymorphisms; however, these results do
suggest  that  the  ability  to  target  Nef  epitopes  with  sufficient
strength that escape associations can be detected population-
wide is a correlate of protection.
HLA-B*44  is  most  frequently  associated  with  sequence
polymorphism  within  Nef  of  any  HLA  allele  and  is  also
consistently  associated  with  some  tendency  to  protection
against disease progression or control of viraemia, amounting
to  approximately  a  0.25  log10  reduction  in  viral  set  point  on
average,  compared  to  a  ~0.75  log10  reduction  for  HLA-B*57:
03,  the  most  protective  HLA  allele  prevalent  in  sub-Saharan
African populations [31,46,56]. We have here defined two novel
HLA-B*44:  03  restricted  epitopes  within  Nef,  KY11
(KEKGGLEGLIY) and QY9 (QEILDLWVY) (Figure 3). KY11 is
entirely  contained  within  OLP-79  which  has  been  associated
with improved disease control overall. Due to the small number
of  HLA-B*44:  03  responders  to  this  OLP  in  our  cohort  (2
responders of a total 91 subjects with HLA-B*44: 03), we have
been  unable  to  determine  whether  recognition  of  the  KY11
epitope itself contributes to control of viraemia. These tetramer-
based  confirmations  of  the  optimal  epitopes  in  this  central
region of Nef highlight the necessity to use these reagents in
order  to  characterize  CTL  responses  that  are  potentially
critically important to immune control.
The  overall  degree  of  sequence  diversity  in  Nef  might
suggest that amino acid substitutions would be well tolerated
without a significant detriment to viral infectivity or replicative
capacity.  However,  a  reversion  rate  of  >50%  (Table  1)
suggests that, even in variable regions of the protein, a fitness
cost to the virus is commonly imposed by the selection of HLA
escape  mutations.  The  polymorphisms  we  identified  do  not
only occur in the epitope-rich central portion of Nef, but also in
the terminal regions of the protein, particularly at the C-terminal
region  (Figure  1).  This  finding  suggests  that  the  C-terminal
region of Nef as well as the central, highly conserved region,
also contains CD8+ T cell epitopes. Potentially these may also
be  important,  but  the  more  variable  regions  of  the  viral
proteome  present  a  considerable  challenge  to  epitope
definition and characterization.
It is striking that SIV epitopes in Nef that are associated with
immune control correspond so specifically to sites of confirmed
or putative HIV HLA-B*57 and B*27 epitopes, and with HIV-
OLPs that are associated with disease control (Figure 4). The
substantial overlap between favourable responses in SIV and
HIV highlights the utility of SIV studies in detecting regions of
the HIV proteome that warrant further attention. However it is
also notable that sequence conservation is not the only factor
contributing to the potential efficacy of Nef-specific responses:
disease  protection  was  only  associated  with  responses  to
OLPs-79 and -85, while responses to OLPs 80-84 which span
this  region  -  and  are  equally  conserved  and  just  as
immunogenic as OLP-79 and OLP-85 - are not associated with
lowered VL (Figure 4). This observation is also highlighted by
other recent studies that report substantial variation in fitness
costs  associated  with  HLA-selected  mutations  irrespective  of
the degree of sequence conservation [62,63].
Overall,  these  results  confirm  the  importance  of  Nef  as  a
CD8+ T cell target with a potentially significant impact on HIV
viraemic  control,  highlight  the  potential  for  HLA  selection  to
drive evolutionary change, and corroborate the predominance
of  the  HLA-B  locus  as  a  selection  force.  The  high  rate  of
reversion  suggests  that  over  half  of  the  HLA  selected
polymorphisms  are  associated  with  a  significant  cost  to  viral
fitness, underlining the usefulness of this protein as a vaccine
target.  Further  studies  to  characterize  the  functional  role  of
these regions of Nef and to define more CD8+ T cell epitopes
will further inform the use of Nef as a vaccine immunogen.
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